13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • NATALEE

    Acronym: 

    NATALEE

    ACTRN/NCT /ethics: 

    NCT03701334

    Scientific title: 

    A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III Tumour Stream Breast Cancer
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2018-12-07
    Molecular Target Anticipated End Date
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Breast Cancer
    Cancer Stage All stages
    Anticipated Start Date 2018-12-07
    Anticipated End Date

    Trial Summary

    A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of Ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer

    Lay Summary

    A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

    Sponsor / Cooperative group

    Novartis Pharmceuticals

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Dr Sina Vatandoust Recruiting